Mirati Therapeutics (MRTX) PT Raised to $225 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Mirati Therapeutics (MRTX) PT Raised to $225 at Oppenheimer
October 28, 2020 5:57 AM EDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00 per share, which consists of 3,960,397 shares to be sold by Mirati and 375,000 shares to be sold by a selling stockholder. The aggregate gross proceeds to Mirati from this offering are expected to be approximately $800.0 million, before... More
October 26, 2020 8:24 AM EDT
Piper Sandler analyst Tyler Van Buren raised the price target on Mirati Therapeutics (NASDAQ: MRTX) to $210.00 (from $170.00) while maintaining an Overweight rating.
The analyst commented, "The adagrasib (formerly MRTX849) Phase Ib/II 45% ORR met investor expectations perour recent flash poll and appears improved versus... More
